RFA-HD-23-003: Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain Barrier (UC2 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $750,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on November 30, 2022.
From the official notice on Grants.gov, last changed September 6, 2022. Checked November 7, 2026.
- Award ceiling$750,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUC2
- Clinical trialsNot allowed
- Funded byNICHD
- Median yearly award$968,830
- Typical project length5 years
Projects funded under RFA-HD-23-003 were run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, 4 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-HD-23-003 in the NIH Guide.
Key dates
| Posted | September 6, 2022 |
|---|---|
| Deadline | November 30, 2022 |
| Archived by Grants.gov | January 5, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $968,830; it allows up to $750,000 per award.
- Most of the money in the 2 programs behind this notice (71% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement invites applications to form Transporter Elucidation Centers (TECs) as part of a Transporter Elucidation Network (TEN). TECs funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) will address key knowledge gaps in functional transport of nutrients and drugs to the developing fetus and infant through a focus on human placenta, lactating mammary gland, and developing gut. Such projects may necessitate deorphanization and characterization of understudied transporters and functional variants. The NICHD-funded TECs will work together to generate knowledge and resources that will be shared with the broader research community to advance our understanding of nutrient, drug, and supplement transport to the developing fetus and infant.
Funded under RFA-HD-23-003 so far
NIH funded 4 projects under RFA-HD-23-003 in fiscal 2023 to 2026, at 4 institutions. The median yearly award was $968,830.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Integrated Transporter Elucidation Center | Rutgers Biomedical and Health Sciences | 2026 | $11,943 |
| Identification, Quantification, and Functional Characterization of Transporters in the Human Placenta and Developing Gut | University of Washington | 2026 | $897,694 |
| Transporter Elucidation Center at the University of California, San Francisco | University of California, San Francisco | 2026 | $968,465 |
| Minerals in Nutrition and Development | Johns Hopkins University | 2026 | $973,697 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Who has won Child Health and Human Development Extramural Research grants before
From fiscal 2021 to 2025, Child Health and Human Development Extramural Research (93.865) awarded $6.0 billion across 6,026 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Regents of the University of Michigan | Michigan | 167 | $178 million |
| The Johns Hopkins University | Maryland | 133 | $146 million |
| University of Washington | Washington | 114 | $131 million |
| Baylor College of Medicine | Texas | 116 | $124 million |
| The Leland Stanford Junior University | California | 104 | $116 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-HD-23-003 still open?
No. It closed on November 30, 2022.
Who can apply for Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain Barrier (UC2 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Elucidation and Validation of the role of Transporters in the Placenta, Lactating Mammary Gland, Developing Gut, and Blood Brain Barrier (UC2 Clinical Trial Not Allowed)?
Closed November 30, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $750,000 each.
Who has been funded under RFA-HD-23-003?
NIH RePORTER lists 4 projects funded under RFA-HD-23-003 in fiscal 2023 to 2026, at 4 institutions. The most were at Rutgers Biomedical and Health Sciences, University of Washington, University of California, San Francisco.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)